CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Remifentanil Injectable Productdrug
Likely dose
Remifentanil Injectable Product 0,15 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03378674
NCT03378674N/ACompleted
CompareCT.gov

Effect of Different Doses of Remifentanil on Stress Response During Laparoscopic Cholecystectomy

Catholic University of the Sacred Heart·interventional·Posted Dec 20, 2017·Updated Jan 8, 2018

In Brief

A clinical study evaluating Remifentanil Injectable Product for Stress Response. Completed, enrolled 50 participants across 1 site.

Detailed Summary

Perioperative adequate analgesia reduces neuroendocrine stress response and postoperative complications. Because opioids are the most effective parenteral drugs to control pain and stress response, in this prospective randomized double-blinded controlled study we supposed that higher dose of remifentanil may reduce stress marker variations compared to lower dose in patients undergoing laparoscopic cholecystectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStress Response
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 20, 2017
Enrollment StartJan 1, 2008
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 8.5 years ago

Interventions

Remifentanil Injectable Productdrug

remifentanil: 0,15 mcg/kg/min